These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20436163)

  • 1. Tumor necrosis factor and anti-tumor necrosis factor therapies.
    Keystone EC; Ware CF
    J Rheumatol Suppl; 2010 May; 85():27-39. PubMed ID: 20436163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases.
    Bressler B; Haraoui B; Keystone E; Sette A
    J Rheumatol Suppl; 2010 May; 85():40-52. PubMed ID: 20436164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From Bedside to Bench: the Role of Anti-Tumor Necrosis Factor Agents in the Management of Immune-Mediated Inflammatory Diseases.
    Haraoui B; Russell AS; Keystone EC
    J Rheumatol Suppl; 2010 May; 85():1. PubMed ID: 20436160
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms for modulating TNF alpha in immune and inflammatory disease.
    Baugh JA; Bucala R
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):635-50. PubMed ID: 12825458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-mediated inflammatory disease.
    Bradley JR
    J Pathol; 2008 Jan; 214(2):149-60. PubMed ID: 18161752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between TNF and glucocorticoid receptor signaling pathways.
    Van Bogaert T; De Bosscher K; Libert C
    Cytokine Growth Factor Rev; 2010 Aug; 21(4):275-86. PubMed ID: 20456998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF antibodies: lessons from the past, roadmap for the future.
    Shealy DJ; Visvanathan S
    Handb Exp Pharmacol; 2008; (181):101-29. PubMed ID: 18071943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF-alpha therapies: the next generation.
    Palladino MA; Bahjat FR; Theodorakis EA; Moldawer LL
    Nat Rev Drug Discov; 2003 Sep; 2(9):736-46. PubMed ID: 12951580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO).
    Chen G; Shi JX; Hang CH; Xie W; Liu J; Liu X
    Neurosci Lett; 2007 Oct; 425(3):177-82. PubMed ID: 17825990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified Si-Miao-San extract inhibits the release of inflammatory mediators from lipopolysaccharide-stimulated mouse macrophages.
    Fan J; Liu K; Zhang Z; Luo T; Xi Z; Song J; Liu B
    J Ethnopharmacol; 2010 May; 129(1):5-9. PubMed ID: 20176100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?
    Soczynska JK; Kennedy SH; Goldstein BI; Lachowski A; Woldeyohannes HO; McIntyre RS
    Neurotoxicology; 2009 Jul; 30(4):497-521. PubMed ID: 19477018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts.
    Sweiss NJ; Curran J; Baughman RP
    Clin Dermatol; 2007; 25(3):341-6. PubMed ID: 17560312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of TNF-alpha and cytokines in the physiopathology of rheumatoid arthritis. Therapeutic perspectives].
    Meyer O
    Bull Acad Natl Med; 2003; 187(5):935-54; discussion 954-5. PubMed ID: 14979058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic.
    Russell AS; Rosenbaum JT
    J Rheumatol Suppl; 2010 May; 85():53-62. PubMed ID: 20436165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases.
    Girolomoni G; Pastore S; Albanesi C; Cavani A
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1590-5. PubMed ID: 12476958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases.
    Taylor PC
    Curr Opin Pharmacol; 2010 Jun; 10(3):308-15. PubMed ID: 20172761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms involved in prostaglandin E2-mediated neuroprotection against TNF-alpha: possible involvement of multiple signal transduction and beta-catenin/T-cell factor.
    Lee EO; Shin YJ; Chong YH
    J Neuroimmunol; 2004 Oct; 155(1-2):21-31. PubMed ID: 15342193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway.
    Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK
    J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases.
    Pereira R; Faria R; Lago P; Torres T
    Curr Drug Saf; 2017; 12(3):162-170. PubMed ID: 28625143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.